Agarwal P, et al. - The authors conducted this analysis to define the utilization of therapies and outcomes for patients with hepatocellular carcinoma (HCC), comparing those managed through their multidisciplinary tumor board (MDTB) to those who were not. They found significantly higher rates of receipt of therapy and improved survival, in patients with HCC managed through a MDTB compared with those who were not.